13. Chronic Lymphocytic Leukemia

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Terry Hamblin and
  2. Angela Hamblin

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch13

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Hamblin, T. and Hamblin, A. (2011) Chronic Lymphocytic Leukemia, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch13

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Department of Immunohaematology, Cancer Sciences Division, University of Southampton, Southampton, UK

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • CLL;
  • IGHV genes;
  • prognostic factors;
  • mRna;
  • TCL1;
  • monoclonal B-cell lymphocytosis;
  • management;
  • autoimmunity;
  • immunodeficiency;
  • ZAP-70


A newly discovered heterogeneity has awakened interest in chronic lymphocytic leukemia (CLL). This has proved to be the key to unlocking the pathophysiology of the condition. A better understanding of molecular pathways is leading to new agents for the control and elimination of the disease. The discovery of a precursor condition, monoclonal B-cell lymphocytosis and its relationship with familial disease has emphasized the hazard of intervention too early in the course of the condition and the need to recognize early signs of progression. A mouse model of progressive disease allows for new treatments to be tested and the availability of purine analogs and monoclonal antibodies have revolutionized treatment. The prospect of cure is now murmured, but as yet curative approaches are ripe with danger. Many patients will still prefer to “live with their disease” but must beware of the risks of immunodeficiency and autoimmunity.